Anti-VEGF Therapy and the Retina: An Update
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Ocular angiogenesis and macular oedema are major causes of sight loss across the world. Aberrant neovascularisation, which may arise secondary to numerous disease processes, can result in reduced vision as a result of oedema, haemorrhage, and scarring. The development of antivascular endothelial growth factor (anti-VEGF) agents has revolutionised the treatment of retinal vasogenic conditions. These drugs are now commonly employed for the treatment of a plethora of ocular pathologies including choroidal neovascularisation, diabetic macular oedema, and retinal vein occlusion to name a few. In this paper, we will explore the current use of anti-VEGF in a variety of retinal diseases and the impact that these medications have had on visual outcome for patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522 · cited 4×
“ANCHOR was a 2-year, randomised, double-blind trial comparing ranibizumab with PDT in predominantly classic subfoveal CNV [11, 33].”
BackgroundMethodInfluentialRanibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Brown, D. M., Michels, M., Kaiser, P. K., Heier, J. S., Sy, J. P., & Ianchulev, T. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.10.018 · Cited by 1,318
Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration
Schmidt-Erfurth, U., Kaiser, P. K., Korobelnik, J.-F., Brown, D. M., Chong, V., Nguyen, Q. D., Ho, A. C., Ogura, Y., Simader, C., Jaffe, G. J., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.08.011 · Cited by 822 · cited 7×
“The BRAVO (𝑛 = 397) and CRUISE (𝑛 = 392) trials were both 3-armed RCTs carried out at multiple centres in the USA.”
ResultInfluentialChakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Culliford, L. A., & Reeves, B. C. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61501-9 · Cited by 748 · cited 1×
“…groups at week 52 were 11.0, 13.1, 9.7, and 12.0 letters for different dosing regimens (0.5mg every 4weeks, 2mg every 4weeks, 2mg every 8weeks after 3 initial monthly doses, and 2mg as needed after 3 initial monthly doses, resp.) versus −1.3 letters for the laser group (𝑃 ≤ 0.0001 versus laser).”
BackgroundInfluentialBusbee, B. G., Ho, A. C., Brown, D. M., Heier, J. S., Suñer, I. J., Li, Z., Rubio, R. G., & Lai, P. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.10.014 · Cited by 500 · cited 1×
“As such, they have evaluated the efficacy of IVB for the treatment of DMO [23].”
BackgroundHolz, F. G., Amoaku, W., Donate, J., Guymer, R. H., Kellner, U., Schlingemann, R. O., Weichselberger, A., & Staurenghi, G. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.12.019 · Cited by 413
Cited by
Melo, G. B., Cruz, N. F. S. D., Emerson, G. G., Rezende, F. A., Meyer, C. H., Uchiyama, S., Carpenter, J., Shiroma, H. F., Farah, M. E., Maia, M., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100862 · Cited by 114
Melo, G. B., Figueira, A. C. M., Batista, F. A. H., Filho, A. A. S. L., Rodrigues, E. B., Belfort, R., & Maia, M. (2019) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/23258160-20190503-05 · Cited by 51
Release of silicone oil droplets from syringes
Melo, G. B., Dias Junior, C. D. S., Carvalho, M. R., Cardoso, A. L., Morais, F. B., Figueira, A. C. M., Lima Filho, A. A. S., Emerson, G. G., & Maia, M. (2019) · International Journal of Retina and Vitreous · doi:10.1186/s40942-018-0153-8 · Cited by 50
Agitation of the syringe and release of silicone oil
Dias Júnior, C. D. S., Cardoso, A. L., Figueiredo, A. G. D. A., Ota, S., & Melo, G. B. (2020) · Eye · doi:10.1038/s41433-020-0800-9 · Cited by 17
Metadata
- Authors
- Tah, V., Orlans, H. O., Hyer, J., Casswell, E., Din, N., Sri Shanmuganathan, V., Ramskold, L., & Pasu, S.
- Venue
- Journal of Ophthalmology
- Publisher
- Hindawi Limited
- Published
- 2015
- Volume
- 2015
- Pages
- 1-13
- ISSN
- 2090-004X (ISSN-L)
- 2090-0058
- OpenAlex
- W1563094820
- Cited by
- 124
- References
- 12
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-VEGF Therapy and the Retina: An Update. https://app.cochat.ai/papers/10.1155/2015/627674
- The paper
- Tah, V., Orlans, H. O., Hyer, J., Casswell, E., Din, N., Sri Shanmuganathan, V., Ramskold, L., & Pasu, S. (2015). Anti-VEGF Therapy and the Retina: An Update. Journal of Ophthalmology. https://doi.org/10.1155/2015/627674
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.